Kymera Therapeutics (KYMR) Change in Account Payables (2019 - 2026)
Kymera Therapeutics (KYMR) reported Change in Account Payables of $8.8 million for Q1 2026, up 125.27% year-over-year from $3.9 million in Q1 2025, and up 691.82% quarter-over-quarter from -$1.5 million in Q4 2025.
Kymera Therapeutics (KYMR) Change in Account Payables (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of Change in Account Payables data on file, last reported at $8.8 million in Q1 2026.
- Change in Account Payables for Q1 2026 came in at $8.8 million, up 125.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 million (down 17.03% YoY), and the FY2025 annual result was -$2.0 million, down 543.0% from the prior year.
- Change in Account Payables grew to $8.8 million in Q1 2026 per KYMR's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $8.8 million in Q1 2026 and troughed at -$4.1 million in Q2 2025.
- A 5-year average of $519647.1 and a median of $31000.0 in 2024 frame the typical range for Change in Account Payables.
- On a YoY basis, Change in Account Payables climbed as much as 5122.67% in 2025 and fell as far as 13432.26% in 2025.
- A 5-year view of Change in Account Payables shows it stood at -$2.1 million in 2022, then jumped by 174.03% to $1.5 million in 2023, then plunged by 132.98% to -$505000.0 in 2024, then sank by 195.25% to -$1.5 million in 2025, then surged by 691.82% to $8.8 million in 2026.
- Business Quant data shows KYMR's Change in Account Payables at $8.8 million in Q1 2026, -$1.5 million in Q4 2025, and -$267000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - | 8.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.82 Mn |
| Mar 31, 2026 | 8.82 Mn |
| Dec 31, 2025 | -1.49 Mn |
| Dec 31, 2025 | -1.49 Mn |
| Sep 30, 2025 | -267,000.00 |
| Sep 30, 2025 | -267,000.00 |
| Jun 30, 2025 | -4.13 Mn |
| Jun 30, 2025 | -4.13 Mn |
| Mar 31, 2025 | 3.92 Mn |
| Mar 31, 2025 | 3.92 Mn |
| Dec 31, 2024 | -505,000.00 |
| Dec 31, 2024 | -505,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 31,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Dec 31, 2023 | 1.53 Mn |
| Dec 31, 2023 | 1.53 Mn |